Natriuretic Peptides as Markers of Left Ventricular Reverse Remodeling After Angiotensin Receptor-Neprilysin Inhibitor Therapy

被引：0
|
作者：
Nakanishi, Koki [1 ,2 ,3 ]
Morita, Hiroyuki [1 ]
机构：
[1] Univ Tokyo, Dept Cardiovasc Med, Tokyo, Japan
[2] Univ Tokyo, Dept Clin Lab, Tokyo, Japan
[3] Univ Tokyo, Dept Cardiovasc Med & Clin Lab, 7-3-1 Hongo Bunkyo Ku, Tokyo 1138655, Japan
来源：
INTERNATIONAL HEART JOURNAL | 2023年 / 64卷 / 06期
关键词：
CHRONIC HEART-FAILURE; SACUBITRIL/VALSARTAN;
D O I：
10.1536/ihj.23-525
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：967 / 969
页数：3
相关论文
共 50 条
  • [41] Clinical and Socioeconomic Determinants of Angiotensin Receptor-Neprilysin Inhibitor Prescription at Hospital Discharge in Patients With Heart Failure With Reduced Ejection Fraction
    Tran, Jeffrey S.
    Loveland, Macklin G.
    Alamer, Ahmad
    Pina, Ileana L.
    Sweitzer, Nancy K.
    CIRCULATION-HEART FAILURE, 2022, 15 (11) : E009395
  • [42] Time to left ventricular reverse remodeling after cardiac resynchronization therapy: Better late than never
    Monteiro, Andre Viveiros
    Oliveira, Mario Martins
    Cunha, Pedro Silva
    da Silva, Manuel Nogueira
    Feliciano, Joana
    Branco, Luisa
    Rio, Pedro
    Pimenta, Ricardo
    Delgado, Ana Sofia
    Ferreira, Rui Cruz
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (03) : 161 - 167
  • [43] Feature article: LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis
    Ge, Qing
    Zhao, Li
    Ren, Xiao-Min
    Ye, Peng
    Hu, Zuo-Ying
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2019, 244 (12) : 1028 - 1039
  • [44] The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line
    Miura, Shin-Ichiro
    Suematsu, Yasunori
    Matsuo, Yoshino
    Tomita, Sayo
    Nakayama, Asuka
    Goto, Masaki
    Arimura, Tadaaki
    Kuwano, Takashi
    Yahiro, Eiji
    Saku, Keijiro
    HYPERTENSION RESEARCH, 2016, 39 (11) : 758 - 763
  • [45] LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Ameliorates Endothelial Dysfunction in Diabetic C57BL/6 Mice
    Munkhjargal, Uugantsetseg
    Fukuda, Daiju
    Maeda, Juri
    Hara, Tomoya
    Okamoto, Shintaro
    Bavuu, Oyunbileg
    Yamamoto, Takayuki
    Sata, Masataka
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2024, 31 (09) : 1333 - 1340
  • [46] Severe Hypotension With Concomitant Sodium-Glucose Co-Transporter-2 Inhibitor and Angiotensin Receptor-Neprilysin Inhibitor Therapy in a Patient With Heart Failure Reduced Ejection Fraction: A Case Report
    Schumacher, Christine
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (02) : 495 - 499
  • [47] Left ventricular reverse remodeling with infantile dilated cardiomyopathy and pitfalls of carvedilol therapy
    Tsuda, Etsuko
    Negishi, Jun
    Noritake, Kanae
    Iwasa, Toru
    Abe, Tadaaki
    JOURNAL OF CARDIOLOGY, 2016, 67 (1-2) : 147 - 152
  • [48] Prevalence and characteristics of patients with clinical improvement but not significant left ventricular reverse remodeling after cardiac resynchronization therapy
    Auger, Dominique
    van Bommel, Rutger J.
    Bertini, Matteo
    Delgado, Victoria
    Ng, Arnold C. T.
    Ewe, See Hooi
    Shanks, Miriam
    Marsan, Nina Ajmone
    Mooyaart, Eline A. Q.
    Witkowski, Tomasz
    Poldermans, Don
    Schalij, Martin J.
    Bax, Jeroen J.
    AMERICAN HEART JOURNAL, 2010, 160 (04) : 737 - 743
  • [49] The power of optimal medical therapy using angiotensin receptor-neprilysin inhibitor in acute decompensated heart failure, sparing a critical patient open-heart surgery with a device therapy: a case report
    Gerges, Fady
    Komaranchath, Austin
    Al Bakshy, Faiz
    Almaghraby, Abdallah
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2021, 5 (02)
  • [50] RETRACTED: Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40% (Retracted Article)
    Zhao, Mingyue
    Xin, Yanguo
    Li, Junli
    Cao, Xiaofan
    Liu, Xiaojing
    MEDICINE, 2019, 98 (39)
12345